Skip to main content

Table 1 Pre screening recommendations for high dose IL-2 therapy

From: High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

  Package insert guidelines Current best practices
Disease MM or mRCC MM: cutaneous better than mucosal/ocular mRCC: clear cell/mixed histology
PS 0-1 0-1
Cardiac function All patients Under 40-50 without history
Thallium stress test-normal Selective testing only
Over 40-50 or prior history
EKG stress test-normal (off beta blockers)
CAD corrected > 6-12 months
EKG stress test, EF, motility-normal
Cardiology consult
Prior TKI
3 month gap if possible
EKG stress test, EF, motility-normal
Abnormal stress test
Cardiology consultation
Pulmonary function All patients Under 40-50 without history
PFTs with ABGs Selective testing only
Over 40-50 or with history of smoking or pulmonary disease
FEV1 ≥ 75% predicted
Brain metastasis No untreated CNS metastasis Negative MRI
Positive MRI
Treated, asymptomatic, off steroids
Infection No active infections No active infections
Renal function All patients Serum creatinine ≤ 1.5 mg/dL
Serum creatinine ≤ 1.5 mg/dL Serum creatinine 1.5-2.0 mg/dL
Creatinine clearance > 60 ml/min
Laboratory All patients Bilirubin ≤ 2.0 mg/dL
Values within normal limits Platelet count > 100,000
Hemoglobin ≥ 9.0 g/100 ml
ANC ≥ 1500/mm3
SGOT < 3x ULN
Thyroid function normal
Other No steroids, autoimmune disease, allografts